Pfizer licences Paxlovid to poor countriesPfizer Inc announced it will allow generic makers in 95 low income nations to produce and distribute its COVID-19 pill Paxlovid at cost price. more ➔
Synthace bags US$35m for R&D cloud pl...London-based Synthace, which develops software to automate biology experimentation, has raised US$35m in a Series C from notable investors. more ➔
EU orders up Valnevas inactivated Covid-...The EU has secured 60 million doses of Valnevas potential Covid-19 vaccine VLA2001. When approvied, it would be the first inactivated vaccine on the EU market. more ➔
LSP and EQT merge to create top-10 investm... Life Sciences investor LSP is set to being acquired by Europe’s largest equity specialist EQT AB. more ➔
Stock market boom: Two biotechs go publicTwo European oncology biopharma companies have made the leap onto the stock market: French MaaT Pharma went public on Euronext Paris, while Danish IO Biotech chose Nasdaq Global Market for its IPO. more ➔
LSP raises a whopping €850m for the Euro...European life science investor LSP has raised €850m for its 7th generation flagship fund LSP 7. more ➔
Novartis inks US-$1.3bn deal with Dunad Th...Dunad Therapeutics Ltd had entered into a $1.3bn option deal with Swiss pharma major Novartis AG to develop targeted protein degrader therapies. more ➔
AstraZeneca unloads respiratory drugs to C...Luxembourg-headquartered Covis is taking two COPD drugs off AstraZenecas hands in a US$270m deal. more ➔
Agomab Therapeutics to acquire Origo Bioph...Belgian Agomab Therapeutics NV is expanding its European footprint by acuiring Barcelona-based fibrosis therapy specialist Origo Biopharma. more ➔
Evotec goes for massive IPO on NasdaqGerman drug discovery company Evotec plans to raise US$576m on the US-American stock exchange Nasdaq to finance extensive investments. more ➔
